About the Company
annan naturvetenskaplig och teknisk forskning och utveckling
Exchange
NASDAQ
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $APRE News
Aprea Therapeutics: Strong Financials and Promising Clinical Pipeline Support Buy Rating
Begin your TipRanks Premium journey today. Aprea Therapeutics (APRE) Company Description: Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and ...
Buy Rating Affirmed: Aprea Therapeutics Poised for Growth with Strong Pipeline Momentum into 2024
Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Aprea Therapeutics (APRE – Research Report), with a price target ...
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly selective ...
APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023
APRE stock results show that Aprea Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.More From InvestorPlace The #1 AI Investment Might ...
Aprea Therapeutics closes equity financing deal valued at up to $34M
A precision oncology company that relocated its headquarters to Bucks County from Boston last year has closed a financing ...
FDA Greenlights Aprea Therapeutics' Investigational New Drug Application for Novel Cancer Treatment
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE), a clinical-stage biopharmaceutical company, has announced that its ...
Atezolizumab Improves Upon Bevacizumab and Chemo in Cervical Cancer
Adding atezolizumab to bevacizumab and platinum chemotherapy improved survival outcomes in patients with advanced cervical ...
Loading the latest forecasts...